Johnson & Johnson $JNJ Shares Sold by Union Bancaire Privee UBP SA

by · The Cerbat Gem

Union Bancaire Privee UBP SA reduced its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 157,258 shares of the company’s stock after selling 3,263 shares during the period. Union Bancaire Privee UBP SA’s holdings in Johnson & Johnson were worth $29,159,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Johnson & Johnson by 1.3% in the second quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC raised its holdings in Johnson & Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after acquiring an additional 1,225,676 shares during the last quarter. Norges Bank purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $4,877,174,000. Bank of New York Mellon Corp boosted its holdings in shares of Johnson & Johnson by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after purchasing an additional 620,039 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Johnson & Johnson by 0.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock valued at $2,894,979,000 after purchasing an additional 52,074 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. HSBC reissued a “buy” rating and set a $240.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday, October 6th. Citigroup boosted their target price on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Finally, Guggenheim raised their price target on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Four analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $208.85.

Get Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Trading Up 0.6%

Shares of JNJ stock opened at $210.50 on Thursday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $215.18. The firm has a market cap of $507.14 billion, a PE ratio of 20.32, a price-to-earnings-growth ratio of 2.27 and a beta of 0.36. The company has a 50-day moving average of $197.44 and a two-hundred day moving average of $178.46. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s payout ratio is presently 50.19%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).